DSpace Repository

Frequency and determinant factors for calcification in neurocysticercosis

Show simple item record

dc.contributor.author Bustos, Javier A.
dc.contributor.author Arroyo, Gianfranco
dc.contributor.author Gilman, Robert H.
dc.contributor.author Soto-Becerra, Percy
dc.contributor.author Gonzales, Isidro
dc.contributor.author Saavedra, Herbert
dc.contributor.author Pretell, E. Javier
dc.contributor.author Nash, Theodore E.
dc.contributor.author O'Neal, Seth E.
dc.contributor.author Del Brutto, Oscar H.
dc.contributor.author Gonzalez, Armando E.
dc.contributor.author Garcia, Hector H.
dc.contributor.author Cysticercosis Working Group in Peru
dc.date.accessioned 2020-07-14T00:00:59Z
dc.date.available 2020-07-14T00:00:59Z
dc.date.issued 2020
dc.identifier.uri https://hdl.handle.net/20.500.12866/8245
dc.description.abstract BACKGROUND: Neurocysticercosis (NCC) is a major cause of acquired epilepsy in most of the world. Larval cysts in the human brain eventually resolve and either disappear or leave a calcified scar that is associated with seizures. This study assessed the proportion of residual calcification in parenchymal NCC, and defined risk factors associated with calcification. METHODS: Data from 220 patients with parenchymal NCC from three randomized trials of antiparasitic treatment was assessed to determine what proportion of the cysts that resolved six months after antiparasitic treatment ended up in a residual calcification at one year. Also, we evaluated the risk factors associated with residual calcification. A multilevel Poisson regression model was used to estimate the risks of calcification. RESULTS: The overall proportion of calcification was 38% (188/497 cysts, from 147 patients). Predictors for calcification at the cyst level were cysts larger than 14 mm (RR 1.34; 95% C.I. 1.02-1.75), and cysts with edema at baseline (RR 1.39; 95% C.I. 1.05-1.85). At the patient level, having had more than 24 months with seizures (RR: 1.25, 95% C.I. 1.08-1.46), mild antibody response (RR: 1.14; 95% C.I. 1.002-1.27), increased dose albendazole regime (RR: 1.26; 95% C.I. 1.14-1.39), lower doses of concomitant dexamethasone (RR: 1.36; 95% C.I. 1.02-1.81), not receiving early antiparasitic re-treatment (RR: 1.45; 1.08-1.93), or complete cure (RR: 1.48; 1.29-1.71). CONCLUSIONS/SIGNIFICANCE: Approximately 38% of parenchymal cysts calcify after antiparasitic treatment. Some factors associated to calcification are modifiable and may be approached to decrease or avoid calcification, potentially decreasing the risk for seizure relapses. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartof urn:issn:1537-6591
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Perú en_US
dc.subject Cysticercosis en_US
dc.subject Taenia solium en_US
dc.subject calcification en_US
dc.subject risk factors en_US
dc.title Frequency and determinant factors for calcification in neurocysticercosis en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/cid/ciaa784
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account